American Thyroid Association Satellite Symposium: Hypothyroidism – Where Are We Now?-Enduring

CLICK "BEGIN" TO EVALUATE SESSIONS, COMPLETE POST-TEST, CLAIM CME, AND PRINT A CERTIFICATE.

Target Audience

This continuing medical education activity should be of substantial interest to the community of endocrinologists, internists, surgeons, basic scientists, nuclear medicine scientists, pathologists, trainees, nurses, physician assistants, other health care professionals and the general public who wish to broaden and update their knowledge on hypothyroidism.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Understand how the therapy of hypothyroidism has evolved since the first use of thyroid gland preparations
  • Describe how TSH references intervals may vary for different populations and understand the impact of TSH values on outcomes, morbidity, and mortality
  • List the factors other than serum TSH values, such as T3 levels and polymorphisms in TH transporters and deiodinases, that may potentially provide information about the thyroid status of patients
  • Describe the potential benefits and risks of combination therapy, and weigh these factors in order to determine whether combination therapy should be offered to patients with hypothyroidism
  • Review areas with significant knowledge gaps, such as whether measuring additional thyroid analytes beyond TSH and FT4 is helpful, and whether diet/dietary supplements impact thyroid function
  • Describe how patient-centered outcomes might be incorporated into the management of patients with hypothyroidism
  •  Appreciate the patient perspective during the treatment of hypothyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credits™
  • 4.50 CME Certificate of Participation
Course opens: 
05/01/2017
Course expires: 
05/01/2018
Rating: 
0
Program Co-Chair
Antonio C. Bianco, MD, PhD
Professor of Medicine 
Rush University Medical Center
Chicago, Illinois
 
Jacqueline Jonklaas, MD
Associate Professor of Medicine
Georgetown University Medical Center
Washington, DC
 
Faculty
Anne R. Cappola, MD
Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
M. Regina Castro, MD
Associate Professor of Medicine 
Mayo Clinic 
Rochester, Minnesota
 
Colin M. Dayan, MA, MBBS, FRCP, PhD
Professor, Clinical Diabetes and Metabolism
Cardiff University School of Medicine
Cardiff, United Kingdom
 
Kimberly Dorris, MBA 
Executive Director and CEO 
Graves' Disease and Thyroid Foundation
 
Alan P. Farwell, MD
Chief, Section of Endocrinology
Diabetes and Nutrition
Boston Medical Center
Boston, Massachusetts
 
James V. Hennessey, MD
Director of Clinical Endocrinology
Beth Israel Deaconess Medical Center
Boston, Massachusetts
 
Philip James
Doctor Thyroid
Portland, Oregon
 
Judy O’Reilly
Retired, 
Winter Garden, Florida
 
Douglas S. Ross, MD
Professor of Medicine, 
Harvard University Medical School  
Co-Director
Massachusetts General Hospital 
Thyroid Clinic
Boston, Massachusetts
 
Anna M. Sawka, MD
Associate Professor
Toronto General Hospital 
University of Toronto 
Toronto, Ontario, Canada
 
Peter N. Taylor, BSc, MBChB, MSc
Welsh Clinical Academic Trainee
Cardiff University School of Medicine
Cardiff, United Kingdom
 
 

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
 
The ATA Guidelines Satellite Symposium faculty reported relevant financial relationship(s):
​​​​​​James V. Hennessey, MD: Consultant, AbbVie Inc., Allergen
Jacqueline Jonklaas, MD: Editorial board, JCEM, Thyroid
 
The ATA Guidelines Satellite Symposium faculty reported no relevant financial relationship(s) during the content development process for this activity: Antonio C. Bianco, MD, PhD; M. Regina Castro, MD; Anne R. Cappola, MD; Colin Mark Dayan MBBS PhD; Kimberly Dorris; Alan P. Farwell, MD; Judy O'Reilly; Douglas S Ross MD; Anna M. Sawka, MD, Peter N. Taylor, BSc, MBChB, MSc
 
The ATA Guidelines Satellite Symposium Program Committee member reported no relevant financial relationship(s): Peter Kopp, MD
 
The following Endocrine Society Special Programs Committee member who reviewed content for this activity reported financial relationships:
Giuseppe Barbesino, MD: Spouse, employee of Genzyme 
 
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexco, Novo Nordisk, Trividia Health
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Alan Kelly, MD: Speaker, Eli Lilly
E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
 
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
 
The following SPC members reported no relevant financial relationships: Connie Newman, MD, Amy Rothberg, MD

Available Credit

  • 4.50 AMA PRA Category 1 Credits™
  • 4.50 CME Certificate of Participation

Accreditation Period

Course opens: 
05/01/2017
Course expires: 
05/01/2018